The recent approval of gene therapy products in Europe and Asia and the upsurge of gene therapy products in clinical trials signal the rebound of this technology not only for many orphan diseases but also for non-life...The recent approval of gene therapy products in Europe and Asia and the upsurge of gene therapy products in clinical trials signal the rebound of this technology not only for many orphan diseases but also for non-life threatening diseases. Following the success of induced pluripotent stem （iPS） cells in research, other modifed ex vivo gene therapies are also knocking on the door of the clinic. Historically, gene therapy has experienced many ups and downs and still faces many challenges.During the past 10 years, many new ideas have been tried, and the goal of making this technology a more effective treatment modality through greater safety and control is coming within reach. The frst clinical trial of iPS cells has begun, and cell mediated gene therapy products have reached phase Ⅲ in some countries. The potential for tumorigenicity and immunogenicity are still concerns with these products, so physicians should understand the biological aspects of engineered cells in the clinic. In this review article, we attempted to provide a summary update of the current state of knowledge regarding this technology： that is, we reviewed products that have fnished clinical trials, are still in clinical trials and/or are at the research stage. We also focused on the challenges, future directions, and strategies for making this technology available in the clinic. In addition, the available measures for making gene therapy products safer are within the scope of this article. It is also important to understand the manufacturing process for gene therapy products, because cell characteristics can change during the cell expansion process. When physicians use gene therapy products in the clinic, they should be aware of the viability, temperature sensitivity and stability of these cells because biologic products are different from chemical products. Although we may not be able to answer all possible questions and concerns, we believe that this is the right time for physicians to increase their interest in and understanding of this evolving technology.展开更多
From the perspective of narratology, this paper explores the contemporary inheritance of the medical legacy of Zhang Zhongjing's practice medicine in the clinic. Its inheritance mode includes: the enrichment of la...From the perspective of narratology, this paper explores the contemporary inheritance of the medical legacy of Zhang Zhongjing's practice medicine in the clinic. Its inheritance mode includes: the enrichment of language and characters and the narratio of romance, the spatial reductive narratio of cultural landscape, the body expressive narratio of ritual behavior. This makes the legend more concerned with the real society, enhances the regional cultural image, develops the local economy, and confidences to the practices role of carrying forward the response and mission of practicing medicine to save people. Compared with the previous academic circle, which previous focus on the textual research of the dispute over its historical authentication, or focus on the retrospective study of its historical origin, this paper is based on the research perspective of historical inheritance, which is constructive to the living inheritance and protection of legends.展开更多
A summary of the exploration of the teaching mode of the general practice teaching clinic, a summary of the deficiencies of the teaching clinic and a summary of the significance of the establishment of the general pra...A summary of the exploration of the teaching mode of the general practice teaching clinic, a summary of the deficiencies of the teaching clinic and a summary of the significance of the establishment of the general practice teaching clinic are presented with a view to promoting the development of general practice and cultivating more excellent successors in general practice.展开更多
Glioma, as the most common and aggressive malignant central nervous system （CNS） tumor with generally poor prognosis, has been attracting much attention in the last decade [1]. Temozolomide was firstly available in ...Glioma, as the most common and aggressive malignant central nervous system （CNS） tumor with generally poor prognosis, has been attracting much attention in the last decade [1]. Temozolomide was firstly available in the United States in 1999 as a chemotherapy drug for treating brain cancers and remains as the first-line treatment for glioma. The World Health Organization （WHO） classified glioma into four main grades according to the degree of malignancy in 2007, which were updated in 2016 with the introduction of significant molecular alternations. Also in 2016, the Chinese Glioma Cooperative Group （CGCG） published the first guideline for adult diffuse gliomas [2], representing the only national consensus for the diagnosis and treatment of adult gliomas up till nOW.展开更多
文摘The recent approval of gene therapy products in Europe and Asia and the upsurge of gene therapy products in clinical trials signal the rebound of this technology not only for many orphan diseases but also for non-life threatening diseases. Following the success of induced pluripotent stem （iPS） cells in research, other modifed ex vivo gene therapies are also knocking on the door of the clinic. Historically, gene therapy has experienced many ups and downs and still faces many challenges.During the past 10 years, many new ideas have been tried, and the goal of making this technology a more effective treatment modality through greater safety and control is coming within reach. The frst clinical trial of iPS cells has begun, and cell mediated gene therapy products have reached phase Ⅲ in some countries. The potential for tumorigenicity and immunogenicity are still concerns with these products, so physicians should understand the biological aspects of engineered cells in the clinic. In this review article, we attempted to provide a summary update of the current state of knowledge regarding this technology： that is, we reviewed products that have fnished clinical trials, are still in clinical trials and/or are at the research stage. We also focused on the challenges, future directions, and strategies for making this technology available in the clinic. In addition, the available measures for making gene therapy products safer are within the scope of this article. It is also important to understand the manufacturing process for gene therapy products, because cell characteristics can change during the cell expansion process. When physicians use gene therapy products in the clinic, they should be aware of the viability, temperature sensitivity and stability of these cells because biologic products are different from chemical products. Although we may not be able to answer all possible questions and concerns, we believe that this is the right time for physicians to increase their interest in and understanding of this evolving technology.
基金Henan Xing Culture Engineering Culture Research Project(2022XWH231)Zhang Zhongjing's Inheritance and Innovation Project(GZY-KJS-2022-039-1,GZY-KJS-2022-043-1,GZY-KJS-2022-045-3)+2 种基金Special Research Project of Traditional Chinese Medicine in Henan Province(2023ZY2194)Research Project of National Museum of Traditional Chinese Medicine(NMTCM-YJ-2022-22)Research Project on Culture and Management of Traditional Chinese Medicine in Henan Province(TCM2020023).
文摘From the perspective of narratology, this paper explores the contemporary inheritance of the medical legacy of Zhang Zhongjing's practice medicine in the clinic. Its inheritance mode includes: the enrichment of language and characters and the narratio of romance, the spatial reductive narratio of cultural landscape, the body expressive narratio of ritual behavior. This makes the legend more concerned with the real society, enhances the regional cultural image, develops the local economy, and confidences to the practices role of carrying forward the response and mission of practicing medicine to save people. Compared with the previous academic circle, which previous focus on the textual research of the dispute over its historical authentication, or focus on the retrospective study of its historical origin, this paper is based on the research perspective of historical inheritance, which is constructive to the living inheritance and protection of legends.
文摘A summary of the exploration of the teaching mode of the general practice teaching clinic, a summary of the deficiencies of the teaching clinic and a summary of the significance of the establishment of the general practice teaching clinic are presented with a view to promoting the development of general practice and cultivating more excellent successors in general practice.
文摘Glioma, as the most common and aggressive malignant central nervous system （CNS） tumor with generally poor prognosis, has been attracting much attention in the last decade [1]. Temozolomide was firstly available in the United States in 1999 as a chemotherapy drug for treating brain cancers and remains as the first-line treatment for glioma. The World Health Organization （WHO） classified glioma into four main grades according to the degree of malignancy in 2007, which were updated in 2016 with the introduction of significant molecular alternations. Also in 2016, the Chinese Glioma Cooperative Group （CGCG） published the first guideline for adult diffuse gliomas [2], representing the only national consensus for the diagnosis and treatment of adult gliomas up till nOW.
